Alexandria Real Estate Equities, Inc. (ARE) Q2 2019 Results - Earnings Call Transcript

Alexandria Real Estate Equities, Inc. (NYSE:ARE) Q2 2019 Earnings Conference Call July 30, 2019 3:00 PM ET

Company Participants

Paula Schwartz - Investor Relations
Joel Marcus - Executive Chairman and Founder
Steve Richardson - Co-Chief Executive Officer
Peter Moglia - Co-Chief Executive Officer & Co-Chief Investment Officer
Dean Shigenaga - Co-President & Chief Financial Officer

Conference Call Participants

Jamie Feldman - Bank of America Merrill Lynch
Manny Korchman - Citi
Rich Anderson - SMBC
Sheila McGrath - Evercore ISI
Michael Carroll - RBC Capital Markets
Daniel Ismail - Green Street Advisors
Tom Catherwood - BTIG
Dave Rodgers - Robert W. Baird

Operator

Good day and welcome to the Alexandria Real Estate Equities Second Quarter 2019 Conference Call. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the conference over to Paula Schwartz with Investor Relations. Please go ahead.

Paula Schwartz

Thank you and good afternoon, everyone. This conference call contains forward-looking statements within the meaning of Federal Securities laws. The company's actual results might differ materially from those projected in the forward-looking statements. Additional information concerning factors that could cause actual results to differ materially from those in the forward-looking statements is contained in the company's periodic reports filed with the Securities and Exchange Commission.

And I would like to turn the call over to Joel Marcus, Executive Chairman and Founder. Please go ahead, Joel.

Joel Marcus

Thank you, Paula and welcome everybody to our second quarter call. With me today are Dean Shigenaga; Steve Richardson; and Peter Moglia. I want to start with focusing on the cover page to our 20 -- our 2Q19 press release and supplemental, which features our recently developed Vertex Pharmaceutical West Coast research base, designed in